Overview

* NeuPath Q3 revenue rises 26% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q3 up 98% yr/yr, marking 27th consecutive positive quarter

* Company attributes growth to optimized clinic footprint and increased patient treatment time

Outlook

* NeuPath expects continued organic and inorganic growth for the balance of 2025 and beyond

* Company anticipates strong demand for Arthrosamid and increased patient visits

Result Drivers

* CLINIC REVENUE - Increase driven by adjustments to physician reimbursement rates and higher demand for fluoroscopy

* CAPACITY UTILIZATION - Improved to 84% in Q3, driven by revenue growth and clinic space optimization

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat C$22.10 C$19.70

Revenue mln mln (1

Analyst)

Q3 C$1.50

Adjusted mln

EBITDA

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for NeuPath Health Inc is C$0.50, about 27% above its November 12 closing price of C$0.37

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)